Ikaros deficiency is associated with aggressive BCR-ABL1 B-cell precursor acute lymphoblastic leukemia independent of the lineage and developmental origin

Haematologica. 2022 Jan 1;107(1):316-320. doi: 10.3324/haematol.2021.279125.
No abstract available

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Fusion Proteins, bcr-abl / genetics
  • Humans
  • Ikaros Transcription Factor / genetics
  • Ikaros Transcription Factor / metabolism*
  • Precursor B-Cell Lymphoblastic Leukemia-Lymphoma* / genetics
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma*

Substances

  • IKZF1 protein, human
  • Ikaros Transcription Factor
  • Fusion Proteins, bcr-abl

Grants and funding

Funding: CS received a predoctoral fellowship from la Ligue Nationale Contre le Cancer (LNCC). This study was supported by grants from Fondation ARC (PJA20171206372 to BH), Agence Nationale de la Recherche (ANR-20-CE15-0011 to BH), LNCC (Equipe Labelissée 2015-2017 to SC), Institut National du Cancer (PLBIO-2015-114 to PK and HC), Agence Nationale de la Recherche (ANR-17-CE15-0023-01 to SC), Fondation pour la Recherche Médicale (Equipe FRM 2019, EQU201903007812), an equipment grant from LNCC Grand Est/Bourgogne Franche Comté (001K.2016 to SC), institute funds from INSERM, CNRS, Université de Strasbourg, and the institute grant ANR-10-LABX-0030-INRT, a French State fund managed by the Agence Nationale de la Recherche under the frame program Investissements d’Avenir ANR-10-IDEX- 0002-02. The GenomEast platform is a member of the France Génomique consortium (ANR-10-INBS-0009).